# Ketamine for Suicidality in Bipolar Depression

> **NCT01944293** · PHASE1,PHASE2 · COMPLETED · sponsor: **New York State Psychiatric Institute** · enrollment: 16 (actual)

## Conditions studied

- Bipolar Disorder
- Major Depressive Episode
- Suicidal Ideation

## Interventions

- **DRUG:** Ketamine
- **DRUG:** Midazolam

## Key facts

- **NCT ID:** NCT01944293
- **Lead sponsor:** New York State Psychiatric Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-09
- **Final completion:** 2018-10
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-03-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01944293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01944293, "Ketamine for Suicidality in Bipolar Depression". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01944293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*